Navigation Links
GeoVax $3.6 Million Award Increased to $4.4 Million by U.S. Government
Date:9/1/2011

icles that display the trimeric membrane bound form of the HIV-1 envelope glycoprotein. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as, the vaccines' safety. Successful results from Phase 1 testing supported the initiation of the first Phase 2 testing. GeoVax's Phase 2 human trial began in January 2009 and involves 300 participants at sites in the United States and South America. Recently GeoVax began enrolling patients in a Phase 1 therapeutic trial for individuals already infected with HIV. For more information, please visit www.geovax.com.

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.  GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so.  More information about these factors is contained in
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. GeoVax Labs, Inc. Announces Second Quarter Financial Results
2. GeoVax Labs HIV/AIDS Vaccine Development Leadership to be Highlighted During 2011 World Vaccine Congress
3. GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases
4. GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine
5. David A. Dodd Appointed Chairman of the Board of GeoVax Labs
6. GeoVax Announces Expansion of Phase 2a Human HIV/AIDS Vaccine Trial
7. GeoVax Awarded Federal Grant Under the Qualifying Therapeutic Discovery Project Program
8. GeoVax Labs Engages The Investor Relations Group
9. GeoVax Labs, Inc. Reports Fourth Quarter and Year End 2009 Financial Results
10. GeoVax Labs, Inc. Plans Public Offering
11. GeoVax Labs, Inc. Begins Enrollment at Final Site for Preventative Vaccine; Next Step Is to Submit IND Application for Therapeutic Vaccine to FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... TIJUANA, Mexico , Dec. 24, 2014 /PRNewswire/ ... treatment of its first patient in its study ... to the American Stroke Association, ischemic strokes account ... continues to enroll qualified patients in the study, ... Intravenous Administration of Allogeneic Mesenchymal Stem Cells and ...
(Date:12/24/2014)... PRINCETON, N.J. , Dec. 24, 2014 /PRNewswire/ ... Company), a late-stage biopharmaceutical company developing products that ... inflammation, oncology and biodefense, announced today that on ... registered public offering. The Company raised ... offering and intends to use the net proceeds ...
(Date:12/24/2014)... and LONDON , December 24, ... industry are expected to grow at an average rate ... of value and volume. Hip, knee and spine surgeries ... while in emerging economies they have a lower penetration. ... challenging the use of composites. Non-metallic orthopedic devices have ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3
... Pharmaceuticals, Inc. (NYSE: WPI ) today ... Watson Laboratories, Inc. -- Florida, (collectively "Watson") filed ... Food and Drug Administration (FDA) seeking approval to ... 20, 30, 40, 60 and 80 mg strengths. ...
... Science (Tianjin) Co. Ltd, a leading research-based contract manufacturer of ... in the U.S. and China, is pleased to announce the ... Quality Assurance as of March 1, 2011. ... in the pharmaceutical industry (early and late stage), in quality ...
Cached Medicine Technology:Watson Confirms OxyContin® Patent Challenge 2Watson Confirms OxyContin® Patent Challenge 3Mr. Robert Andrews Joins Asymchem Life Science (Tianjin) Co. Ltd. as Vice President of Quality Assurance 2
(Date:12/25/2014)... December 26, 2014 The ... combines beauty, strength and durability. Today, the business ... which is valid until Jan. 30, 2015. , ... of traditional hardwood. BambooFlooringChina.com is a well-known brand ... consumers worldwide to find a reliable bamboo flooring ...
(Date:12/25/2014)... iFitDress.com, the popular online supplier of wedding dresses and special ... black one-shoulder cocktail dresses . In addition, all these ... discounted prices, up to 70% off. , The ... only. You know, we have thousands of frequent callers in ... items can visit our website for more details. The current ...
(Date:12/25/2014)... 25, 2014 Helen Harris’ RP (Retinitis ... Hills, California after an 8 year battle with breast ... Eve evening in her home in Woodland Hills California ... cancer. , As the founder and ... she pioneered and championed many of today's greatest breakthroughs ...
(Date:12/25/2014)... 25, 2014 (HealthDay News) -- Overeating is common during the ... in moderation, an expert says. "Don,t arrive at a ... if you know you,ll be attending a party, but deprivation ... lead dietitian at Northern Westchester Hospital in Mount Kisco, N.Y., ... eat healthy during the day and even to have a ...
(Date:12/25/2014)... December 25, 2014 “ SmileStix ” was ... features the latest and coolest mobile applications on the iOS, ... and host of NewsWatch, conducted the app review and shared ... create personal stickers. , The old saying goes, “A picture ... of words that can describe a single image, because each ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... for bowel cancer at Queen,s University Belfast has received ... Dr Sandra Van Schaeybroeck, whose research aims to identify ... a prestigious 688,000 Cancer Research UK Clinical Scientist Fellowship. ... four fellowships awarded to UK clinical investigators, renews Dr ...
... ,Surgeons aged 35 to 50 provide the safest care for ... about ongoing training and motivation of surgeons during their careers, ... France. They analyzed data from 3,574 thyroidectomies (removal of ... over a one-year period. The average age of the surgeons ...
... , TUESDAY, Jan. 10 (HealthDay News) -- Children with autism ... bacteria seen in kids who do not have the disorder, ... 10 in the online journal mBio , researchers from ... New York City suggested that this finding could help explain ...
... patients improved between 2003 and 2008, according to a ... Outcomes , an American Heart Association journal. The study ... of care, and that differences in care between the ... because little is known about the treatment and outcomes ...
... By Serena Gordon HealthDay Reporter , TUESDAY, Jan. ... new research suggests those costs may extend far beyond the ... study authors found that young people with diabetes were more ... lifetime, could expect to earn about $160,000 less than those ...
... that older Americans with cirrhosis have significantly worse health ... this potentially deadly disease. In fact, findings now published ... American Association for the Study of Liver Diseases, show ... of informal caregiving and contribute added strain on the ...
Cached Medicine News:Health News:Groundbreaking cancer research receives massive funding boost 2Health News:Surgeons in Mid-Career Have Fewest Complications: Study 2Health News:Autism Gastro Problems May Be Linked to Gut Bacteria 2Health News:Asian-Americans getting better heart attack care 2Health News:Diabetes Takes a Toll on Lifetime Earnings: Study 2Health News:Diabetes Takes a Toll on Lifetime Earnings: Study 3Health News:Diabetes Takes a Toll on Lifetime Earnings: Study 4Health News:High rates of disability and health care use for older americans with cirrhosis 2
The Stryker CBCII Blood Conservation System provides a safe, simple and economic disposable system for blood reinfusion....
The Rapid Programmer 3.0 is the smallest and lightest-weight clinician programming platform in the industry. It enables clinicians to quickly and efficiently test patients intraoperatively and to cre...
... systems are intended to provide ventricular antitachycardia ... of life-threatening ventricular arrhythmias. In patients indicated ... systems are also intended:, to provide ... to severe heart failure (NYHA Functional Class ...
Used for implantation to reinforce soft tissue where weakness exists. Indications for use include repair of a hernia or body wall defect. Supplied sterile in peel-open packages. Intended for one-time...
Medicine Products: